<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02476773</url>
  </required_header>
  <id_info>
    <org_study_id>SVI-DBL-01</org_study_id>
    <nct_id>NCT02476773</nct_id>
  </id_info>
  <brief_title>Study of Na-APR-1 (M74)/Alhydrogel® Co-administered With Na-GST-1/Alhydrogel in Brazilian Adults</brief_title>
  <official_title>Phase 1 Study of the Safety and Immunogenicity of Na-APR-1 (M74)/Alhydrogel® Co-administered With Na-GST-1/Alhydrogel® in Brazilian Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centro de Pesquisas René Rachou</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>George Washington University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Na-GST-1 and Na-APR-1 are proteins expressed during the adult stage of the Necator americanus&#xD;
      hookworm life cycle that are thought to play a role in the parasite's degradation of host&#xD;
      hemoglobin for use as an energy source. Vaccination wtih recombinant GST-1 or APR-1 has&#xD;
      protected dogs and hamsters from infection in challenge studies. This study will evaluate the&#xD;
      safety and immunogenicity of co-administering Na-GST-1 and Na-APR-1 to healthy Brazilian&#xD;
      adults living in an area of endemic hookworm infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Double blind, randomized, controlled, dose-escalation Phase 1 clinical trial in hookworm&#xD;
      exposed adults living in the area of Americaninhas, Minas Gerais, Brazil. Subjects will&#xD;
      receive three doses of the assigned vaccine delivered intramuscularly on approximately Days&#xD;
      0, 56, and 112.&#xD;
&#xD;
      Safety will be measured from the time of each study vaccination (Day 0) through 14 days after&#xD;
      each study vaccination by the occurrence of solicited injection site and systemic&#xD;
      reactogenicity events.&#xD;
&#xD;
      Unsolicited non-serious adverse events (AEs) will be collected from the time of the first&#xD;
      study vaccination through approximately 1 month after each study vaccination. New-onset&#xD;
      chronic medical conditions and Serious Adverse Events (SAEs) will be collected from the time&#xD;
      of the first study vaccination through approximately 9 months after the third study&#xD;
      vaccination (final visit). Clinical laboratory evaluations for safety will be performed on&#xD;
      venous blood collected approximately 14 days after each vaccination.&#xD;
&#xD;
      Immunogenicity testing will include IgG antibody responses to each vaccine antigen, by an&#xD;
      indirect enzyme-linked immunosorbent assay (ELISA) and also by ImmunoCAP, on serum obtained&#xD;
      prior to each study vaccination and at time points after each vaccination; antibody affinity&#xD;
      by Surface Plasmon Resonance; functional activity of vaccine-induced antibodies via in vitro&#xD;
      enzyme neutralization assays; and, antigen-specific memory B cell responses.&#xD;
&#xD;
      Recruitment and enrollment into the study will occur on an ongoing basis, with each group&#xD;
      being recruited and vaccinated in sequence.&#xD;
&#xD;
      60 subjects will be enrolled into 6 groups of 10.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of solicited injection site and systemic reactogenicity, graded by severity, on the day of each study vaccination through 14 days after each study vaccination.</measure>
    <time_frame>14 days post-vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of study vaccine-related serious adverse events from the time of the first study vaccination through approximately 9 months after the last study vaccination.</measure>
    <time_frame>Day 380</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of clinical safety laboratory adverse events.</measure>
    <time_frame>Day 380</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of unsolicited adverse events, graded by severity, from the time of each study vaccination through approximately 1 month after each study vaccination.</measure>
    <time_frame>30 days post-vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of new-onset chronic medical conditions through approximately 9 months after the third study vaccination.</measure>
    <time_frame>Day 380</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Adverse Events of Special Interest through approximately 9 months after the third study vaccination.</measure>
    <time_frame>Day 380</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The IgG level by an indirect enzyme-linked immunosorbent assay (ELISA) on approximately Day 126.</measure>
    <time_frame>Day 126</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>The IgG antibody response, by an indirect enzyme-linked immunosorbent assay (ELISA) at approximately 7, 14, and 28 days after each vaccination, and approximately 3, 6, and 9 months after the third dose.</measure>
    <time_frame>7, 14, and 28 days after each vaccination, and approximately 3, 6, and 9 months after the third dose</time_frame>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Hookworm Infection</condition>
  <condition>Hookworm Disease</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 subjects will receive 10µg Na-APR-1 (M74)/Alhydrogel with Sterile Saline Placebo administered to the alternate arm.&#xD;
5 subjects will receive 10µg Na-APR-1 (M74)/Alhydrogel with 100µg Na-GST-1/Alhydrogel plus GLA-AF administered to the alternate arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 subjects will receive 10µg Na-APR-1 (M74)/Alhydrogel plus GLA-AF, with Sterile Saline Placebo administered to the alternate arm.&#xD;
5 subjects will receive 10µg Na-APR-1 (M74)/Alhydrogel plus GLA-AF, with 100µg Na-GST-1/Alhydrogel plus GLA-AF administered to the alternate arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 subjects will receive 30µg Na-APR-1 (M74)/Alhydrogel, with Sterile Saline Placebo administered to the alternate arm.&#xD;
5 subjects will receive 30µg Na-APR-1 (M74)/Alhydrogel, with 100µg Na-GST-1/Alhydrogel plus GLA-AF administered to the alternate arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 subjects will receive 30µg Na-APR-1 (M74)/Alhydrogel plus GLA-AF, with Sterile Saline Placebo administered to the alternate arm.&#xD;
5 subjects will receive 30µg Na-APR-1 (M74)/Alhydrogel plus GLA-AF, with 100µg Na-GST-1/Alhydrogel plus GLA-AF administered to the alternate arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 subjects will receive 100µg Na-APR-1 (M74)/Alhydrogel, with Sterile Saline Placebo administered to the alternate arm.&#xD;
5 subjects will receive 100µg Na-APR-1 (M74)/Alhydrogel, with 100µg Na-GST-1/Alhydrogel plus GLA-AF administered to the alternate arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 subjects will receive 100µg Na-APR-1 (M74)/Alhydrogel plus GLA-AF, with Sterile Saline Placebo administered to the alternate arm.&#xD;
5 subjects will receive 100µg Na-APR-1 (M74)/Alhydrogel plus GLA-AF, with 100µg Na-GST-1/Alhydrogel plus GLA-AF administered to the alternate arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Na-GST-1/Alhydrogel plus GLA-AF</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Na-APR-1 (M74)/Alhydrogel</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Na-APR-1 (M74)/Alhydrogel plus GLA-AF</intervention_name>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sterile Saline Placebo</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males or non-pregnant females between 18 and 45 years, inclusive.&#xD;
&#xD;
          2. Good general health as determined by means of the screening procedure.&#xD;
&#xD;
          3. Available for the duration of individual subject study participation (16 months).&#xD;
&#xD;
          4. Willingness to participate in the study as evidenced by signing the informed consent&#xD;
             document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy as determined by a positive urine hCG (if female).&#xD;
&#xD;
          2. Subject unwilling to use reliable contraception (as described in Section 2.3.1) from&#xD;
             30 days prior to the first immunization and up until one month following the third&#xD;
             immunization (if female and not surgically sterile, abstinent or at least 2 years&#xD;
             post-menopausal, or determined otherwise by medical evaluation to be sterile).&#xD;
&#xD;
          3. Currently lactating and breast-feeding (if female).&#xD;
&#xD;
          4. Inability to correctly answer all questions on the informed consent comprehension&#xD;
             questionnaire.&#xD;
&#xD;
          5. Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic,&#xD;
             rheumatologic, autoimmune, diabetes, or renal disease by history, physical&#xD;
             examination, and/or laboratory studies (a history of essential hypertension that is&#xD;
             well controlled by medication will not be considered exclusionary.)&#xD;
&#xD;
          6. Has a diagnosis of schizophrenia, bipolar disease or other major psychiatric condition&#xD;
             that would make compliance with study visits/procedures difficult (e.g., subject with&#xD;
             psychoses or history of suicide attempt or gesture in the 3 years before study entry,&#xD;
             ongoing risk for suicide).&#xD;
&#xD;
          7. Known or suspected immunodeficiency.&#xD;
&#xD;
          8. Laboratory evidence of liver disease (alanine aminotransferase [ALT] greater than&#xD;
             1.25-times the upper reference limit).&#xD;
&#xD;
          9. Laboratory evidence of renal disease (serum creatinine greater than 1.25-times the&#xD;
             upper reference limit, or more than trace protein or blood on urine dipstick testing&#xD;
             with the exception of greater than trace blood detected in females during menses).&#xD;
&#xD;
         10. Laboratory evidence of hematologic disease (absolute leukocyte count &lt;3200/mm3;&#xD;
             absolute leukocyte count &gt;10.8 x 103/mm3; hemoglobin &lt;11.4 g/dl [females] or &lt;12.1&#xD;
             g/dl [males]; or, platelet count &lt;130,000/mm3).&#xD;
&#xD;
         11. Serum glucose (random) greater than 1.2-times the upper reference limit.&#xD;
&#xD;
         12. Other condition that in the opinion of the investigator would jeopardize the safety or&#xD;
             rights of a volunteer participating in the trial or would render the subject unable to&#xD;
             comply with the protocol.&#xD;
&#xD;
         13. Participation in another investigational vaccine or drug trial within 30 days of&#xD;
             starting this study.&#xD;
&#xD;
         14. Previous receipt of the Na-GST-1/Alhydrogel® hookworm vaccine.&#xD;
&#xD;
         15. Volunteer has had medical, occupational, or family problems as a result of alcohol or&#xD;
             illicit drug use during the past 12 months.&#xD;
&#xD;
         16. History of a severe allergic reaction or anaphylaxis.&#xD;
&#xD;
         17. Severe asthma as defined by the need for daily use of inhalers or emergency clinic&#xD;
             visit or hospitalization within the last 6 months.&#xD;
&#xD;
         18. Positive test for hepatitis B surface antigen (HBsAg).&#xD;
&#xD;
         19. Positive confirmatory test for HIV infection.&#xD;
&#xD;
         20. Positive confirmatory test for hepatitis C virus (HCV) infection.&#xD;
&#xD;
         21. Use of corticosteroids (excluding topical or nasal) or immunosuppressive drugs within&#xD;
             30 days of the volunteer's expected first vaccination in this study or planned use up&#xD;
             to one month following the last vaccination.&#xD;
&#xD;
         22. Receipt of a live vaccine within past 4 weeks or a killed vaccine within past 2 weeks&#xD;
             prior to the volunteer's expected first vaccination in the study.&#xD;
&#xD;
         23. History of a surgical splenectomy.&#xD;
&#xD;
         24. Receipt of blood products within the past 6 months.&#xD;
&#xD;
         25. Anti-Na-GST-1 IgE antibody level above 0.35 kUA/L by the ImmunoCAP method.&#xD;
&#xD;
         26. Anti-Na-APR-1 IgE antibody level above ELISA reactivity threshold.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Diemert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>George Washington University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rodrigo Correa-Oliveira, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Centro de Pesquisas René Rachou</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Americaninhas Vaccine Center</name>
      <address>
        <city>Americaninhas</city>
        <state>Minas Gerais</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>June 17, 2015</study_first_submitted>
  <study_first_submitted_qc>June 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2015</study_first_posted>
  <last_update_submitted>November 29, 2019</last_update_submitted>
  <last_update_submitted_qc>November 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Maria Elena Bottazzi PhD</investigator_full_name>
    <investigator_title>Sponsor</investigator_title>
  </responsible_party>
  <keyword>Hookworm Vaccine</keyword>
  <keyword>Na-APR-1 (M74)/Alhydrogel® Hookworm Vaccine</keyword>
  <keyword>Na-GST-1/Alhydrogel® Hookworm Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hookworm Infections</mesh_term>
    <mesh_term>Ancylostomiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aluminum Hydroxide</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 22, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/73/NCT02476773/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 1, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/73/NCT02476773/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

